ACAD News and Press, ACADIA Pharmaceuticals Inc. From 09/15/25

2025-09-15 20:21:09 ET This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers’ 13F stock portfolio on a quarterly basis. It is based on Baker Brothers’ regulatory 13F Form filed on 08/14/2025. The 13F portfolio value in...

-- Findings reinforce efficacy and tolerability profile in patients prescribed DAYBUE in the U.S. for as long as 12 months, consistent with the Phase 3 LAVENDER™ trial that supported FDA approval and open-label LILAC, LILAC-2 and DAFFODIL studies Acadia Pharmaceuticals Inc. (Na...

2025-08-27 10:06:16 ET Shares of RNA medicine concern Stoke Therapeutics, Inc. ( STOK ) have more than tripled off their recent lows in early April. Stoke's antisense oligonucleotide zorevunersen has demonstrated significant seizure reduction in Dravet syndrome patie...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: Morgan Stanley 23rd Annual Global Healthcare Conference Fireside Chat: Monday, September 8, 2025 at 10:45 a.m. Eastern Time in New York, NY H.C. Wainwright 2...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Konstantina (“Tina”) Katcheves as Senior Vice President, Chief Business and Strategy Officer. In this role, Tina will lead Acadia’s business development and corporate strategy and serve as a member ...

2025-08-07 03:58:32 ET More on Acadia Pharma ACADIA Pharmaceuticals Inc. (ACAD) Q2 2025 Earnings Call Transcript Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview ACADIA Pharmaceuticals: Advancing On Several Fronts Acadia Pharma Q2 2025 Earni...

2025-08-07 03:57:55 ET ACADIA Pharmaceuticals Inc. (ACAD) Q2 2025 Earnings Conference Call August 06, 2025, 4:30 PM ET Company Participants Al Kildani - Corporate Participant Catherine E. Owen Adams - CEO & Director Elizabeth H. Z. Thompson - Executive VP and...

2025-08-06 16:18:46 ET More on Acadia Pharma Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview ACADIA Pharmaceuticals: Advancing On Several Fronts Acadia gets court approval related to Nuplazid patent Acadia Pharmaceuticals jumps after win in...

- Second quarter total revenues of $264.6 million, up 9% year-over-year - Second quarter NUPLAZID ® (pimavanserin) net product sales of $168.5 million, up 7% year-over-year - Second quarter DAYBUE ® (trofinetide) net product sales of $96.1 million, up 14% year-ov...

2025-08-06 10:00:00 ET Major earnings expected after the bell on Wednesday include: Realty Income Corporation ( O ) Energy Transfer LP ( ET ) Occidental Petroleum Corporation ( OXY ) Airbnb ( ABNB ) DraftKings ( DKNG ) Read the full article ...